A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2019
At a glance
- Drugs IONIS-HBV-LRx (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline KK
- 08 Jan 2019 Planned End Date changed from 28 Jan 2019 to 8 Nov 2019.
- 08 Jan 2019 Planned primary completion date changed from 4 Nov 2018 to 31 Jan 2019.
- 30 Aug 2018 Status changed from recruiting to active, no longer recruiting.